Brokerages Set Teladoc Health, Inc. (NYSE:TDOC) PT at $7.50

Teladoc Health, Inc. (NYSE:TDOC) has been given an average recommendation of “Hold” by the sixteen ratings firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, ten have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $7.50.

Several analysts have recently commented on the stock. Canaccord Genuity Group reduced their price target on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Thursday. Citigroup lifted their target price on Teladoc Health from $6.00 to $7.00 and gave the company a “neutral” rating in a research report on Tuesday, May 5th. Bank of America upped their price target on Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Finally, Weiss Ratings upgraded Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 22nd.

Key Stories Impacting Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Teladoc reported a second-quarter adjusted loss of $0.21 per share, better than the consensus estimate of a $0.24 loss. Strength in Integrated Care and international operations helped offset weakness in BetterHelp. Teladoc Health Q2 Earnings Beat Estimates on Integrated Care Strength
• Positive Sentiment: Management’s cost controls and efficiency measures appear to be narrowing losses over the first half of 2026, while some investors see the stock as potentially undervalued following the selloff. Teladoc Health Could Be Undervalued
• Neutral Sentiment: Canaccord Genuity maintained a Buy rating but lowered its price target from $11 to $10. Separately, traders purchased about 15,650 call options, roughly 30% above typical volume, suggesting some speculative bullish positioning but not necessarily a change in fundamentals.
• Negative Sentiment: Second-quarter revenue fell 4% year over year to $606.9 million, missing analysts’ $615.4 million estimate. Teladoc also posted a $38.9 million net loss, or $0.21 per share, compared with a $0.19 loss in the year-earlier quarter. Teladoc Tumbles on Revenue Forecast Cut
• Negative Sentiment: The key pressure is BetterHelp, where shifting demand reduced cash-pay revenue. After a 12% annual decline in the latest quarter, the company indicated the division could decline as much as 19% for the full year, undermining expectations for a recovery. Teladoc Health Investigation Notice
• Negative Sentiment: Teladoc’s third-quarter revenue outlook of approximately $589 million was below expectations, and the company lowered its full-year revenue forecast. The weaker outlook outweighed the adjusted earnings beat and caused analysts and investors to reset expectations for growth and profitability. Teladoc Stock Plummets on Revenue Miss and Lowered Outlook
• Negative Sentiment: Levi & Korsinsky announced a pending investigation into Teladoc, adding potential legal and reputational risk to an already weak earnings narrative. The investigation notice does not establish wrongdoing, but it may further weigh on sentiment.

Teladoc Health Trading Up 0.0%

Shares of TDOC opened at $6.71 on Friday. Teladoc Health has a 12-month low of $4.40 and a 12-month high of $9.89. The firm has a 50-day moving average price of $8.21 and a 200 day moving average price of $6.54. The firm has a market capitalization of $1.21 billion, a P/E ratio of -6.78 and a beta of 2.10.

Teladoc Health (NYSE:TDOC) last issued its earnings results on Wednesday, July 29th. The health services provider reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.04. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. The company had revenue of $606.93 million for the quarter, compared to the consensus estimate of $615.44 million. During the same period in the previous year, the firm earned ($0.19) earnings per share. Teladoc Health’s quarterly revenue was down 4.0% compared to the same quarter last year. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. Equities research analysts predict that Teladoc Health will post -0.88 earnings per share for the current fiscal year.

Insider Activity at Teladoc Health

In related news, insider Fernando M. Rodrigues sold 5,677 shares of the stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total transaction of $43,315.51. Following the completion of the transaction, the insider owned 9,572 shares of the company’s stock, valued at approximately $73,034.36. This trade represents a 37.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Adam C. Vandervoort sold 7,906 shares of Teladoc Health stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total transaction of $60,322.78. Following the completion of the sale, the insider owned 110,261 shares of the company’s stock, valued at $841,291.43. This trade represents a 6.69% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 39,195 shares of company stock worth $299,058. 0.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Teladoc Health

A number of institutional investors have recently modified their holdings of the company. EverSource Wealth Advisors LLC lifted its stake in Teladoc Health by 694.5% during the 1st quarter. EverSource Wealth Advisors LLC now owns 5,657 shares of the health services provider’s stock worth $31,000 after acquiring an additional 4,945 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in Teladoc Health by 177.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock worth $31,000 after purchasing an additional 2,810 shares during the period. IFP Advisors Inc increased its stake in Teladoc Health by 412.1% during the third quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock worth $31,000 after purchasing an additional 3,210 shares during the period. International Assets Investment Management LLC acquired a new stake in shares of Teladoc Health during the fourth quarter worth about $45,000. Finally, Van ECK Associates Corp lifted its position in shares of Teladoc Health by 101.4% during the fourth quarter. Van ECK Associates Corp now owns 9,150 shares of the health services provider’s stock worth $64,000 after purchasing an additional 4,607 shares in the last quarter. 76.82% of the stock is owned by institutional investors and hedge funds.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.